The present study indicates that BRCA1/BRCA2 mutation carriers with ER-positive tumors have a poor prognosis with increased BC recurrence and BC-related death rate; therefore, their specific treatment (surgical and pharmacological prevention) should be considered. The gene discussed is BRCA2; the disease is breast cancer.